"Astrazeneca going beyond - reshaping the blockbuster business model"

Revalska, Petya Sergeeva

http://hdl.handle.net/10362/144641

Utilize este identificador para referenciar este registo.

Nome:	Descrição:	Tamanho:	Formato:
2021-22_fall_44668_petya-revalska.pdf		1.26 MB	Adobe PDF	Ver/Abrir

Contacte-nos

Autores

Revalska, Petya Sergeeva

Orientador(es)

André, Rosário

Resumo(s)

AstraZeneca (AZN) is a global, science-led biopharmaceutical company focused on on the discovery, development, and commercialisation drugs, primarily for the treatment of diseases in three main areas Oncology, Cardiovascular, Respiratory. From 2021 AstraZeneca added anew segment to its business ±Rare Diseases by acquiring Alexion Pharmaceutical, Inc. This paper aims to value AstraZeneca by using methods such as discounted cash flows and trading multiples. I intend to estimate the company enterprise value as of 30-12-2022 and provide an investment recommendation for 12-month period.

Palavras-chave

Valuation Finance Covid-19 pandemic Astrazeneca Alexion Oncology Rare diseases Collaboration agreements Drug Sales Blockbuster Business Model Acquisition Pharmaceuticals